Core Insights - AIX has been listed on LBank Exchange, with the AIX/USDT trading pair going live on June 15, 2025, providing access to a platform that integrates artificial intelligence and decentralized data economics [1][2][3] Company Overview - AIX is a decentralized platform aimed at enhancing AI training and data productivity, built on a distributed ledger to empower creators and institutions through transparent data corroboration and tokenized incentives [3][4] - The platform addresses the challenges of centralized AI development by returning value and control to data contributors, utilizing blockchain verification and AI tooling [4][5] Market Positioning - AIX targets the growing global AI training market, which is approaching $100 billion, positioning itself as a key infrastructure for equitable growth and data monetization [6] - The platform aims to mitigate centralization risks posed by monopolistic AI platforms through community governance [5] Technical Innovations - The AIX ecosystem incorporates various technical features, including DAO governance, smart contract-based reward distribution, and an automated market maker (AMM) mechanism inspired by Uniswap V2/V3 for token exchange [7] Tokenomics - AIX has a total supply of 1,000,000,000 AIX tokens, with a distribution model that includes a community incentive pool (40%), core development team (20%), strategic investors (15%), partner ecosystem fund (10%), reserve fund (10%), and public governance fund (5%) [8][13] - The platform will implement a deflationary model, using 20% of its revenue for buybacks and burns, alongside early participation rewards for contributors and validators [14] Governance and Compliance - AIX plans to transition to community governance, ensuring decisions are driven by AIX pledges, while maintaining full audit transparency and regulatory compliance [16]

Core Viewpoint - The Company has announced an interim dividend of 0.75 pence per share and a special dividend of 0.50 pence per share following its unaudited interim results for the six-month period ending 31 March 2025 [2]. Dividend Details - The ex-dividend date is set for 26 June 2025 [2]. - The record date for the dividend is 27 June 2025 [2]. - The payment date for the dividends is scheduled for 25 July 2025 [2]. - The last date for receipt of elections regarding the Dividend Re-investment Scheme (DRIS) is 11 July 2025, with further announcements to follow [2].

Core Viewpoint - The Company reported a decline in net asset value (NAV) and total return for the six months ending March 31, 2025, reflecting challenging market conditions and investment performance [3][4][13]. Financial Highlights - NAV per share decreased from 40.55p to 34.48p, representing a total return of -8.19% [4][13]. - Market capitalization fell from £150.60 million to £124.25 million [4]. - Share price also declined from 42.20p to 33.80p, with a share price discount to NAV per share of 1.97% [4]. - Dividends paid per share increased from 1.50p to 2.75p during the period [4][6]. Investment Activity - The Company invested £3.6 million in qualifying companies during the period, maintaining 92.29% of its portfolio in qualifying investments [6][30]. - An offer for subscription launched on October 9, 2024, aimed to raise up to £20 million, with £5.4 million raised by issuing 14 million shares [6][31]. Performance of Qualifying Investments - Positive contributors included Aquis Exchange (+95.8%, +£1.71 million) and Cohort (+26.1%, +£1.12 million) due to increased defense spending [15][16]. - Negative contributors included Kidly (-100.00%, -£1.26 million) which went into administration, and Zoo Digital (-74.3%, -£1.14 million) which issued a disappointing trading update [20][21]. Non-Qualifying Investments - The non-qualifying portfolio saw a decline of £1.27 million, with notable losses in WH Smith and Hollywood Bowl due to a weaker economic outlook [27][28]. - The fixed income portfolio returned +£0.35 million, offsetting some losses from direct equities [29]. Market Outlook - The UK economy is expected to see a modest GDP growth of +1.0% in 2025, supported by increased public spending despite inflation concerns [10][39]. - The AIM index has shown resilience post 'Liberation Day', indicating potential growth opportunities despite ongoing market volatility [12][40]. Portfolio Structure - The Company maintained a strong liquidity position with net cash of £11.7 million and a focus on recurring revenue, which represented 82% of total revenue [26][29]. - The portfolio's weighting to qualifying investments increased to 58.4%, while cash weighting decreased to 7.6% [36].

Core Viewpoint - Kenmare Resources plc has terminated discussions regarding a potential offer from a consortium led by Oryx Global Partners Limited, citing that the proposals significantly undervalued the company and its prospects [3][12]. Company Overview - Kenmare Resources plc is a leading global producer of titanium minerals and zircon, operating the Moma Titanium Minerals Mine in northern Mozambique [3]. - The company is confident in its independent prospects and ability to achieve strategic and operational objectives, with a strong order book for the second half of 2025 [5]. Offer Discussions - Initial discussions began on March 6, 2025, when Kenmare received a non-binding proposal from the consortium for an all-cash offer at a price of 530 pence per share [7]. - The Board of Kenmare unanimously rejected the initial proposal, deeming it to undervalue the company [8]. - Subsequent engagement with the consortium revealed that they were only willing to proceed with an offer at a price substantially below the initial proposal, which was also rejected by the Board [11]. Future Plans - Kenmare is progressing with the Wet Concentrator Plant A upgrade project, with commissioning expected to begin in Q3 2025 [6]. - Ongoing discussions with the Government of Mozambique regarding the extension of the Implementation Agreement highlight the company's commitment to its investments and future plans in the region [7].

Core Insights - Transgene's TG4050 has demonstrated 100% Disease-Free Survival (DFS) after a minimum of two years in the Phase I part of the clinical trial, confirming its clinical proof of principle [1][2] - The company is progressing with the Phase II part of the trial, expecting to complete patient randomization by the end of 2025, with initial immunogenicity data anticipated in H2 2026 and preliminary efficacy data in H2 2027 [3][4] Company Overview - Transgene is a biotechnology company focused on developing virus-based immunotherapies for cancer treatment, with TG4050 being its lead asset based on the myvac® platform [7][10] - The myvac® platform utilizes artificial intelligence from NEC to optimize antigen selection for individualized cancer treatment [8][10] Clinical Trial Details - The Phase I/II clinical trial for TG4050 targets HPV-negative squamous head and neck cancers, with approximately 80 patients expected to be enrolled and randomized [3][12] - The trial evaluates the efficacy of TG4050 as an adjuvant treatment following surgery and adjuvant therapy, with a focus on patients at risk of relapse [12] Future Developments - Transgene is preparing for a new Phase I trial in a second, undisclosed indication, aiming to initiate it in Q4 2025 [5][11] - The company is committed to advancing the development of TG4050 and enhancing its manufacturing capabilities to meet the demands of a competitive market [4][11]

Core Insights - SBM Offshore has signed an operations and maintenance contract with TotalEnergies EP Suriname B.V. for the FPSO GranMorgu, which is part of the field development project in Block 58, Suriname [1][12] - The contract includes operation readiness before first oil and maintenance services for a minimum of two years post-first oil, with options for extension [1] Company Strategy and Positioning - This contract strengthens SBM Offshore's long-term strategic partnership with TotalEnergies and establishes SBM Offshore as the first FPSO operator in Suriname [2] - The achievement reflects SBM Offshore's commitment to excellence throughout the project's lifecycle, leveraging their Fast4Ward MPF hull and extensive asset management experience [2] Corporate Profile - SBM Offshore is recognized as a global expert in deepwater ocean infrastructure, focusing on the design, construction, installation, and operation of offshore floating facilities [3] - The company aims to contribute to cleaner and more efficient energy production while exploring new markets within the blue economy [3] Workforce and Collaboration - SBM Offshore employs over 7,800 professionals worldwide, dedicated to delivering innovative solutions and promoting a sustainable future [4]

Core Insights - Vallourec has secured a significant contract worth over $50 million to supply Oil Country Tubular Goods (OCTG) for drilling operations in Qatar, with deliveries scheduled for 2026 [1][2] - The contract aligns with Qatar's plans to increase oil production by 19% and liquefied natural gas (LNG) production by 85% by 2030, necessitating additional drilling and infrastructure development [2][3] - Vallourec has a long-standing presence in Qatar and aims to remain a key strategic partner in various energy projects, including oil, gas, and carbon capture initiatives [3] Company Overview - Vallourec is a global leader in premium seamless tubular solutions, catering to energy markets and demanding industrial applications [3] - The company employs nearly 13,000 people across more than 20 countries, focusing on innovative and competitive tubular solutions [3][4] - Vallourec is listed on Euronext in Paris and is part of several indices, including CAC Mid 60 and SBF 120 [4]

Group 1 - The analyst has over 20 years of experience covering airlines, specifically LATAM Airlines (NYSE: LTM), and anticipated that many airlines would seek Chapter 11 protection during the Covid pandemic due to high debt and fixed costs impacting cash flow [1] - The analyst has a diverse background in analyzing various industries including airlines, oil, retail, mining, fintech, and e-commerce, along with macroeconomic, monetary, and political factors [1] - The analyst has lived through multiple crises, including the tequila crisis, the dot-com bubble, 9/11, the Great Recession, and the Covid-19 pandemic, which has contributed to a robust base of experience applicable across multiple disciplines [1] Group 2 - The analyst holds a beneficial long position in the shares of LTM through stock ownership, options, or other derivatives, indicating a personal investment in the company [2] - The article expresses the analyst's own opinions and is not influenced by compensation from any company mentioned [2]

Core Insights - TGS, in collaboration with Viridien, has launched Laconia Phase III, a significant ocean bottom node (OBN) survey program in the Gulf of America, covering approximately 150 OCS blocks [1][2] - The program aims to provide Ultra Long Offset OBN data using advanced technologies, enhancing geophysical imaging clarity and targeting the Paleogene play in the central Keathley Canyon area [2][4] - Initial products from the Laconia Phase III survey are expected to be delivered in Q1 2026, with the acquisition phase ongoing through Q3 2025 [3] Company Overview - TGS is recognized as a global leader in energy data and intelligence, offering advanced data solutions across the energy value chain [5][6] - The company emphasizes its commitment to delivering high-quality seismic solutions to support the energy industry [4] - TGS's collaboration with Viridien leverages both companies' strengths to provide high-impact datasets for offshore exploration [4]

Core Viewpoint - Addex Therapeutics reported a strong start to 2025 with significant progress in product development and business milestones, particularly in their GABAB PAM drug candidate for chronic cough and the mGlu2 PAM asset ADX71149 [2][5]. Financial Summary - Income for Q1 2025 was CHF 71,000, a decrease of CHF 164,000 from CHF 235,000 in Q1 2024 [4]. - R&D expenses decreased to CHF 156,000 from CHF 245,000, a reduction of CHF 89,000 [4][8]. - G&A expenses decreased to CHF 521,000 from CHF 778,000, a reduction of CHF 257,000 [4][8]. - Total operating loss improved to CHF 606,000 from CHF 788,000, an improvement of CHF 182,000 [4]. - Net loss from continuing operations was CHF 1,473,000, compared to CHF 735,000 in Q1 2024, reflecting an increase of CHF 738,000 [4]. - Net loss for the period decreased to CHF 1,473,000 from CHF 3,087,000, a reduction of CHF 1,614,000 [4]. - Basic and diluted net loss per share was CHF 0.01, down from CHF 0.03 in the same period last year [4][10]. - Cash and cash equivalents increased to CHF 2.8 million from CHF 1.6 million, an increase of CHF 1.2 million [4][11]. - Shareholders' equity improved significantly to CHF 8.3 million from a negative CHF 1.4 million [4]. Operational Highlights - The GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in multiple disease models [5][6]. - The company regained rights to its Phase 2 mGlu2 PAM asset, ADX71149 [5][6]. - Indivior successfully advanced their GABAB PAM program for substance use disorders through IND enabling studies [5][6]. - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [5][6]. Additional Information - The Q1 2025 financial report is available on the company's website [12]. - A conference call was scheduled to review the financial results, featuring CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev [13].